CAMLINFINE Camlin Fine Q2 FY25 results (Jul–Sep 2024) and concall
Camlin Fine Sciences delivered a strong operational performance in Q2 FY25, marked by revenue growth and significant margin expansion, primarily driven by its Aroma and Blends segments. The quarter also saw strategic impairments related to its European diphenol and Chinese operations, aiming to streamline the business and reduce future losses. Despite high debt levels and ongoing liquidity challenges, management expressed confidence in the growth trajectory of its core businesses and the positive impact of anti-dumping duties.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 417 |
| EBITDA | 52 |
| Net profit | -116 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
